Results 61 to 70 of about 3,474,042 (288)

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Mutational signatures in 175 Chinese gastric cancer patients

open access: yesBMC Cancer
Background Gastric cancer (GC), a molecularly heterogeneous disease, is the third leading cause of cancer death worldwide. The majority of GC cases worldwide occur in East Asia, predominantly China.
Fatao Liu   +18 more
doaj   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

open access: yesAdvanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang   +21 more
wiley   +1 more source

Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973–2007 [PDF]

open access: yesInternational Journal of Circumpolar Health, 2012
Objectives: To describe the occurrence of pancreatic, biliary tract, and gallbladder cancers within the Alaska Native (AN) population. Study design: Population-based analysis utilizing a tumor registry and comparative population data.
Steven R. Alberts   +3 more
doaj   +1 more source

Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies.

open access: yes, 2019
Background: Tobacco and alcohol are well-established risk factors for numerous cancers, yet their relationship to biliary tract cancers remains unclear. Methods: We pooled data from 26 prospective studies to evaluate associations of cigarette smoking and
Neuhouser, Marian L   +113 more
core   +1 more source

Multifunctional Zinc Glycyrrhizinate‐Integrated Gel for Enhanced Probiotic Delivery and Alleviation of Acute and Spontaneous Colitis

open access: yesAdvanced Science, EarlyView.
Multifunctional oral delivery system—L. reuteri@ZGM—act as both a carrier and therapeutic adjuvant, providing ROS scavenging, and mucin‐interactive properties tailored to the IBD microenvironment. This bioactive gel safeguards L. reuteri from gastric degradation, enhances mucosal adhesion, and promotes long‐term retention at inflamed sites, thereby ...
Mengyun Peng   +8 more
wiley   +1 more source

An RNA–RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity

open access: yesSignal Transduction and Targeted Therapy, 2021
Hepatocellular carcinoma (HCC) is the global leading cause of cancer-related deaths due to the deficiency of targets for precision therapy. A new modality of epigenetic regulation has emerged involving RNA–RNA crosstalk networks where two or more ...
Yanping Wei   +17 more
doaj   +1 more source

The Antidiabetic Potential of Alpha‐Mangostin: A Review of Preclinical and Clinical Evidence

open access: yesAgriFood: Journal of Agricultural Products for Food, EarlyView.
Alpha‐mangostin is a compound from the pericarp of Garcinia mangostana. The antidiabetic effects of alpha‐mangostin include enhancing insulin secretion, improving glucose uptake through GLUT receptor upregulation, reducing oxidative stress and inflammation, promoting wound healing, reducing HbA1C, reducing HOMA‐IR index, and decreased mRNA expressions ...
Oliver Dean John   +4 more
wiley   +1 more source

Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe

open access: yes, 1998
cancer survival - liver cancer- pancreatic cancer - biliary tract ...
FAIVRE J.   +6 more
core   +1 more source

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

open access: yesNature Communications, 2023
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation ...
James J. Harding   +27 more
doaj   +1 more source

Home - About - Disclaimer - Privacy